Wearing a mask when in a public setting, staying a safe distance away from other people, and following CDC recommendations relative disinfecting and personal hygiene can help slow the spread of COVID-19. This is key to improving health and to our economic recovery.
Joan Koerber-Walker, president & CEO, AZBio #MaskUpAZ #MaskUpArizona
Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplant recipients.
TUCSON, Ariz., June 17, 2020 — Critical Path Institute (C-Path) announced today that its Transplant Therapeutics Consortium (TTC) has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program (BQP).Continue reading
Chandler, Arizona – The Biotechnology Innovation Organization (BIO) released new data on the bioscience industry in the United States. The new report, The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State & Local Communities, analyzes the bioscience industry’s economic footprint across the nation and in Arizona, the significant role of small- and mid-sized companies, and the industry’s response to the COVID-19 pandemic.Continue reading
Select Sessions From BIO Digital Week Now Available!Continue reading
CDC reports drop in recommended child vaccinationsContinue reading
PHOENIX, Ariz.– Humabiologics Inc., a regenerative medicine company founded by scientists and tissue industry experts, announced today it has successfully raised $1 million in seed funding.Continue reading
Tucson, Ariz. & Scottsdale, Ariz. / June 4, 2020
Research Corporation Technologies, Inc. (RCT) announced today that it has acquired and invested growth capital into Translational Drug Development (TD2), the leading fully integrated precision oncology medicine development organization.
TD2 provides end-to-end solutions, including translational preclinical services; regulatory strategic guidance, planning and document submission services; and clinical trial design and execution for innovative oncology-focused companies.Continue reading
IMNA Solutions announced today that it has appointed Russ Yelton, President/CEO of Yelton and Associates and Chairman of The Board of Trustees of AZAdvances to its board of directorsContinue reading